vs
卡彭特科技（CRS）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是卡彭特科技的1.1倍（$772.1M vs $728.0M），卡彭特科技净利率更高（14.5% vs 12.7%，领先1.7%），卡彭特科技同比增速更快（7.5% vs 5.9%），Revvity自由现金流更多（$161.8M vs $85.9M），过去两年Revvity的营收复合增速更高（9.0% vs 3.1%）
卡彭特科技是全球特种合金材料供应商，主营不锈钢、耐腐蚀镍、铜、钛合金及3D增材制造用粉末合金的研发、生产与分销。2018财年其营收分布为：航空航天与国防占55%，工业与消费品占17%，医疗占8%，交通、能源各占7%，分销业务占6%。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CRS vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$728.0M
营收增速更快
CRS
高出1.7%
5.9%
净利率更高
CRS
高出1.7%
12.7%
自由现金流更多
RVTY
多$75.9M
$85.9M
两年增速更快
RVTY
近两年复合增速
3.1%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $728.0M | $772.1M |
| 净利润 | $105.3M | $98.4M |
| 毛利率 | 30.0% | — |
| 营业利润率 | 21.3% | 14.5% |
| 净利率 | 14.5% | 12.7% |
| 营收同比 | 7.5% | 5.9% |
| 净利润同比 | 25.2% | 3.9% |
| 每股收益（稀释后） | $2.09 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRSRVTY
| Q4 25 | $728.0M | $772.1M | ||
| Q3 25 | $733.7M | $698.9M | ||
| Q2 25 | $755.6M | $720.3M | ||
| Q1 25 | $727.0M | $664.8M | ||
| Q4 24 | $676.9M | $729.4M | ||
| Q3 24 | $717.6M | $684.0M | ||
| Q2 24 | $798.7M | $691.7M | ||
| Q1 24 | $684.9M | $649.9M |
净利润CRSRVTY
| Q4 25 | $105.3M | $98.4M | ||
| Q3 25 | $122.5M | $46.7M | ||
| Q2 25 | $111.7M | $53.9M | ||
| Q1 25 | $95.4M | $42.2M | ||
| Q4 24 | $84.1M | $94.6M | ||
| Q3 24 | $84.8M | $94.4M | ||
| Q2 24 | $93.6M | $55.4M | ||
| Q1 24 | $6.3M | $26.0M |
毛利率CRSRVTY
| Q4 25 | 30.0% | — | ||
| Q3 25 | 29.5% | 53.6% | ||
| Q2 25 | 28.3% | 54.5% | ||
| Q1 25 | 27.6% | 56.5% | ||
| Q4 24 | 26.2% | — | ||
| Q3 24 | 24.6% | 56.3% | ||
| Q2 24 | 23.9% | 55.7% | ||
| Q1 24 | 21.5% | 54.6% |
营业利润率CRSRVTY
| Q4 25 | 21.3% | 14.5% | ||
| Q3 25 | 20.9% | 11.7% | ||
| Q2 25 | 20.1% | 12.6% | ||
| Q1 25 | 19.0% | 10.9% | ||
| Q4 24 | 17.6% | 16.3% | ||
| Q3 24 | 15.8% | 14.3% | ||
| Q2 24 | 13.6% | 12.4% | ||
| Q1 24 | 11.1% | 6.8% |
净利率CRSRVTY
| Q4 25 | 14.5% | 12.7% | ||
| Q3 25 | 16.7% | 6.7% | ||
| Q2 25 | 14.8% | 7.5% | ||
| Q1 25 | 13.1% | 6.4% | ||
| Q4 24 | 12.4% | 13.0% | ||
| Q3 24 | 11.8% | 13.8% | ||
| Q2 24 | 11.7% | 8.0% | ||
| Q1 24 | 0.9% | 4.0% |
每股收益（稀释后）CRSRVTY
| Q4 25 | $2.09 | $0.86 | ||
| Q3 25 | $2.43 | $0.40 | ||
| Q2 25 | $2.21 | $0.46 | ||
| Q1 25 | $1.88 | $0.35 | ||
| Q4 24 | $1.66 | $0.77 | ||
| Q3 24 | $1.67 | $0.77 | ||
| Q2 24 | $1.85 | $0.45 | ||
| Q1 24 | $0.12 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $231.9M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.0B | $7.3B |
| 总资产 | $3.5B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CRSRVTY
| Q4 25 | $231.9M | $919.9M | ||
| Q3 25 | $208.0M | $931.4M | ||
| Q2 25 | $315.5M | $991.8M | ||
| Q1 25 | $151.5M | $1.1B | ||
| Q4 24 | $162.1M | $1.2B | ||
| Q3 24 | $150.2M | $1.2B | ||
| Q2 24 | $199.1M | $2.0B | ||
| Q1 24 | $53.5M | $1.7B |
股东权益CRSRVTY
| Q4 25 | $2.0B | $7.3B | ||
| Q3 25 | $1.9B | $7.4B | ||
| Q2 25 | $1.9B | $7.6B | ||
| Q1 25 | $1.8B | $7.6B | ||
| Q4 24 | $1.7B | $7.7B | ||
| Q3 24 | $1.7B | $7.9B | ||
| Q2 24 | $1.6B | $7.9B | ||
| Q1 24 | $1.5B | $7.8B |
总资产CRSRVTY
| Q4 25 | $3.5B | $12.2B | ||
| Q3 25 | $3.4B | $12.1B | ||
| Q2 25 | $3.5B | $12.4B | ||
| Q1 25 | $3.4B | $12.4B | ||
| Q4 24 | $3.3B | $12.4B | ||
| Q3 24 | $3.3B | $12.8B | ||
| Q2 24 | $3.3B | $13.4B | ||
| Q1 24 | $3.2B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $132.2M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $85.9M | $161.8M |
| 自由现金流率自由现金流/营收 | 11.8% | 21.0% |
| 资本支出强度资本支出/营收 | 6.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.26× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $316.7M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CRSRVTY
| Q4 25 | $132.2M | $182.0M | ||
| Q3 25 | $39.2M | $138.5M | ||
| Q2 25 | $258.1M | $134.3M | ||
| Q1 25 | $74.2M | $128.2M | ||
| Q4 24 | $67.9M | $174.2M | ||
| Q3 24 | $40.2M | $147.9M | ||
| Q2 24 | $169.5M | $158.6M | ||
| Q1 24 | $83.5M | $147.6M |
自由现金流CRSRVTY
| Q4 25 | $85.9M | $161.8M | ||
| Q3 25 | $-3.4M | $120.0M | ||
| Q2 25 | $200.2M | $115.5M | ||
| Q1 25 | $34.0M | $112.2M | ||
| Q4 24 | $38.6M | $149.8M | ||
| Q3 24 | $13.3M | $125.6M | ||
| Q2 24 | $141.8M | $136.6M | ||
| Q1 24 | $61.9M | $129.7M |
自由现金流率CRSRVTY
| Q4 25 | 11.8% | 21.0% | ||
| Q3 25 | -0.5% | 17.2% | ||
| Q2 25 | 26.5% | 16.0% | ||
| Q1 25 | 4.7% | 16.9% | ||
| Q4 24 | 5.7% | 20.5% | ||
| Q3 24 | 1.9% | 18.4% | ||
| Q2 24 | 17.8% | 19.7% | ||
| Q1 24 | 9.0% | 20.0% |
资本支出强度CRSRVTY
| Q4 25 | 6.4% | 2.6% | ||
| Q3 25 | 5.8% | 2.6% | ||
| Q2 25 | 7.7% | 2.6% | ||
| Q1 25 | 5.5% | 2.4% | ||
| Q4 24 | 4.3% | 3.4% | ||
| Q3 24 | 3.7% | 3.3% | ||
| Q2 24 | 3.5% | 3.2% | ||
| Q1 24 | 3.2% | 2.7% |
现金转化率CRSRVTY
| Q4 25 | 1.26× | 1.85× | ||
| Q3 25 | 0.32× | 2.97× | ||
| Q2 25 | 2.31× | 2.49× | ||
| Q1 25 | 0.78× | 3.03× | ||
| Q4 24 | 0.81× | 1.84× | ||
| Q3 24 | 0.47× | 1.57× | ||
| Q2 24 | 1.81× | 2.87× | ||
| Q1 24 | 13.25× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRS
| Aerospace And Defense Markets | $448.8M | 62% |
| Industrial And Consumer Markets | $88.4M | 12% |
| Performance Engineered Products Segment | $83.2M | 11% |
| Medical Market | $54.7M | 8% |
| Energy Market | $48.5M | 7% |
| Transportation Market | $21.2M | 3% |
| Distribution Market | $17.2M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
